Meniu
Asmeninė anketa Prisijungimas ir registracija
Atgal » » » 2020 » Spalio » 20

Neuropilin-1 drives SARS-CoV-2 infectivity, finds breakthrough study

Neuropilin-1 drives SARS-CoV-2 infectivity, finds breakthrough study

In a major breakthrough an international team of scientists, led by the University of Bristol, has potentially identified what makes SARS-CoV-2 highly infectious and able to spread rapidly in human cells. The findings, published in Science today [20 October] describe how the virus's ability to infect human cells can be reduced by inhibitors that block a newly discovered interaction between virus and host, demonstrating a potential anti-viral treatment.

Unlike other coronavirus, which cause common colds and mild respiratory symptoms, SARS-CoV-2, the causative agent of COVID-19, is highly infective and transmissive. Until now, major questions have remained unanswered as to why SARS-CoV-2 readily infects organs outside of the respiratory system, such as the brain and heart.

To infect humans, SARS-CoV-2 must first attach to the surface of human cells that line the respiratory or intestinal tracts. Once attached, the virus invades the cell then replicates multiple copies of itself. The replicated viruses are then released leading to the transmission of SARS-CoV-2.

The virus's process of attachment to and invasion of human cells is performed by a viral protein, called the 'Spike' protein. Understanding the process by which the 'Spike' protein recognises human cells is central to the development of antiviral therapies and vaccines to treat COVID-19.

In this breakthrough study, the research groups in Bristol's Faculty of Life Sciences, Professor Peter Cullen from the School of Biochemistry; Dr. Yohei Yamauchi, Associate Professor and virologist from the School of Cellular and Molecular Medicine, and Dr. Boris Simonetti, a senior researcher in the Cullen lab, used multiple approaches to discover that SARS-CoV-2 recognises a protein called neuropilin-1 on the surface of human cells to facilitate viral infection.

Credit: University of Bristol

Yohei, Boris and Pete explained: "In looking at the sequence of the SARS-CoV-2 Spike protein we were struck by the presence of a small sequence of amino acids that appeared to mimic a protein sequence found in human proteins which interact with neuropilin-1. This led us to propose a simple hypothesis: could the Spike protein of SARS-CoV-2 associate with neuropilin-1 to aid viral infection of human cells? Excitingly, in applying a range of structural and biochemical approaches we have been able to establish that the Spike protein of SARS-CoV-2 does indeed bind to neuropilin-1.

"Once we had established that the Spike protein bound to neuropilin-1 we were able to show that the interaction serves to enhance SARS-CoV-2 invasion of human cells grown in cell culture. Importantly, by using monoclonal antibodies—lab-created proteins that resemble naturally occurring antibodies—or a selective drug that blocks the interaction we have been able to reduce SARS-CoV-2's ability to infect human cells. This serves to highlight the potential therapeutic value of our discovery in the fight against COVID-19."

Intriguingly, scientists at the Technical University of Munich, Germany and the University of Helsinki, Finland, have independently found that neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.

Together the Bristol researchers concluded: "To defeat COVID-19 we will be relying on an effective vaccine and an arsenal of anti-viral therapeutics. Our discovery of the binding of the SARS-CoV-2 Spike to neuropilin-1 and its importance for viral infectivity provides a previously unrecognised avenue for anti-viral therapies to curb the current COVID-19 pandemic."

  • by University of Bristol
  • Neuropilin-1 (NRP1) is a host factor for SARS-CoV-2 infection. This is an image of human cells incubated with SARS-CoV-2, infected cells are labelled green. Removal of NRP1 drastically reduces SARS-CoV-2 infection in human cell cultures. Reduction of infection can also be observed when cells were treated with a drug or an antibody targeting NRP1. Credit: The University of Bristol

Turite savo nuomone, (už ar, prieš) pasidalinkite su mumis, palikite komentarą, prisijunkite, rašykite bloge, pasirinkdami kategoriją. Pasidalinkite savo receptais, sveikatos patarimais, nutikimais, susidūrėte su paranormaliais, anomališkais ir kitais nekasdieniškais reiškiniais. Galite išversti iš užsienio kalbos, talpinkite su nuoroda. Laukiame Jūsų straipsnių, naujienų, apžvalgų ar istorijų!

Įvertink šį straipsnį. Prieš tai pakomentuodami, arba parašykite patys! Norėdami tobulėti, suteikiame jums galimybę įvertinti skaitomą PARANORMAL turinį. Norite sužinoti daugiau, sutikite gauti naujienas arba pasidalinkite spausdami .
Niekas neišdrįso palikti komentaro.
Būkite pirmi, kurie pasidalins savo nuomonėmis su kitais.
avatar
TAIP PAT SKAITYKITE:
04.12.2020 laikas 22:58 Johns-Hopkins researcher says CDC data show COVID-19 has NO effect on percentage of death in older people
When all is said and done, Americans — and the world — are going to discover that while the COVID-19 virus is real as was the pandemic, virtually nothing we’ve been told about the infection morbidity rates has been accurate....

Skaityti daugiau

04.12.2020 laikas 22:38 Election findings could ‘Easily’ overturn 3 states, data analyst concludes
WASHINGTON—The former data and strategy director for President Donald Trump’s 2016 election campaign says he has found enough evidence to suggest the election results could be “easily” turned to favor the current president....

Skaityti daugiau

04.12.2020 laikas 22:03 Moderna to start testing its mRNA COVID-19 vaccine on children – are parents really letting their kids serve as guinea pigs?
Moderna has announced that it will start testing its COVID-19 vaccine in children in a large, late-stage trial. The U.S. National Library of Medicine’s registry indicates that the study will include 3,000 participants aged 12 to 17....

Skaityti daugiau

04.12.2020 laikas 21:27 Namų vaistinėlė: Putinai gelbsti nuo peršalimo
Putinų arbatos skonis ir aromatas man pažįstami nuo vaikystės. Močiutė visada ruošdavo šį gėrimą, kai šeimoje kas nors susirgdavo peršalimo ligomis.

Skaityti daugiau

04.12.2020 laikas 21:04 Citrina prieš hipertoniją ir reumatizmą
Jei pajutote nemalonius pojūčius gerklėje, perštėjimą, neskubėkite griebtis medikamentų. Jums puikiai gali padėti citrinų nuoviras. Į nedidelį emaliuotą puodą išspauskite 3 citrinų sultis, truputį pašildykite ant mažos ugnies, nevirinkite....

Skaityti daugiau

04.12.2020 laikas 20:37 Namų vaistinėlė: 4 receptai nuo kosulio
ik kosuliui prasidėjus, padės imbieras, iš tarkuotos imbiero šaknies (1 šaukštas), citrinos ir medaus paruoškite arbatą. Ją gerkite kas 1-1,5 valandos. Sloga praeis po 1-2 stiklinių, o kosulys - po 5-6. Dar patartina sukramtyti česnako skiltelių....

Skaityti daugiau